Savient Pharmaceuticals appoints president of Savient Europe
David Veitch takes up the role
Veitch brings extensive commercial knowledge of the European Union across marketing, sales, market access and general management to the US biopharmaceutical firm. He will be responsible for establishing, building and leading Savient's European regional organisation to launch and drive the future growth of Krystexxa (pegloticase), a drug for the treatment of chronic gout in adult patients refractory to conventional therapy.
Savient submitted its European Marketing Authorisation Application (MAA) for Krystexxa in May 2011, and anticipates EU approval in the second half of 2012.
Veitch joins Savient with more than 24 years of pharmaceutical industry experience at Bristol- Myers Squibb and SmithKline Beecham Pharmaceuticals, and has extensive knowledge across many therapy areas including: oncology, virology, CV-Metabolism, CNS and immunology.
Most recently he was senior vice president of European marketing and brand commercialisation at Bristol Myers Squibb.
Prior to that, Veitch spent 10 years in a number of leadership positions at Bristol-Myers Squibb.
You may also like
Ingredients
![UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny]()
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny
The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Pharmaceutical
![OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics]()
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics
The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows
Pharmaceutical
![Pharma’s silent sustainability risk and the supply chain fix]()
Pharma’s silent sustainability risk and the supply chain fix
Pharma is making efforts to cut emissions from its own operations: shifting to renewables, upgrading facilities, streamlining logistics²⁰. But a significant share of emissions still hides outside the company’s direct control – yet in plain sight. Now, regulators and investors are turning their focus beyond the factory gates, deep into the value chain. What they’re finding is already reshaping the rules of competitiveness, capital access, and compliance. One of pharma’s most overlooked risks is quietly moving into the foreground. And the time to act is narrowing
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![From speed to strategy: how UK life sciences should respond to China’s rise]()
From speed to strategy: how UK life sciences should respond to China’s rise
A group of biotech founders, big pharma leaders, clinical and CMC specialists, and CDMO executives gathered at a recent dinner sponsored by AsymChem to discuss a question now sitting in many boardrooms: what is China’s maturing biopharma ecosystem doing to the global industry, and how should UK companies respond?